Only 15% of patients admitted to the hospital with COVID-19 received monoclonal antibodies.

We revised this check on Nov 7, 2026. See what changed and why ↓

The finding

What remains unresolved

McCullough gives a 15% inpatient-use figure without identifying its dataset or period; this review could not verify that number. The FDA's November 2020 authorization for casirivimab/imdevimab excluded patients hospitalized because of COVID and warned of possible worse outcomes in some severely ill groups. That explains why low inpatient use need not mean improper withholding, but does not refute the numerical claim.

Read the supporting source · www.fda.gov ↗

Quick answer & review status

Quick answer

Is it true that only 15% of patients admitted to the hospital with COVID-19 received monoclonal antibodies?

We can't say yet. McCullough gives a 15% inpatient-use figure without identifying its dataset or period; this review could not verify that number. The FDA's November 2020 authorization for casirivimab/imdevimab excluded patients hospitalized because of COVID and warned of possible worse outcomes in some severely ill groups. Dr. Peter McCullough said it (matched by voice) on Joe Rogan Experience #2576 - Dr. Peter McCullough, aired Nov 4, 2026, at 56:53. We couldn't settle it from the evidence we captured, so it stays an open question, not a false claim. The supporting source is fda.gov, linked below.

The context belongs here.

No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.

Attribution: Not independently confirmed in this record
Editorial context review: Not recorded; generated finding
Coverage: One selected claim from the episode

Revisions to this check

Nov 7, 2026

Previously: Only 15% of patients admitted to the hospital with COVID-19 received monoclonal antibodies. [Distorted]: The claim suggests hospitals held back a treatment from admitted patients, but these antibodies were never cleared for that use. When the FDA authorized them, it said they were for outpatients with mild to moderate COVID and were not authorized for people hospitalized because of COVID, so a low rate among inpatients was expected. We also could not find any study behind the 15% figure. A study showing hospitals routinely denied authorized antibody treatment to eligible patients would prove this verdict wrong.

Now: Only 15% of patients admitted to the hospital with COVID-19 received monoclonal antibodies. [Unverified]: McCullough gives a 15% inpatient-use figure without identifying its dataset or period; this review could not verify that number. The FDA's November 2020 authorization for casirivimab/imdevimab excluded patients hospitalized because of COVID and warned of possible worse outcomes in some severely ill groups. That explains why low inpatient use need not mean improper withholding, but does not refute the numerical claim.

Use unverified for an unlocated statistic instead of treating authorization context as a numerical disproof.

Evidence for the revision ↗

Challenge this finding or add context →

Stay curious. Stay up to date.

Keep the evidence coming.

Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.

Follow the RSS feed

Email signup is currently unavailable.

Prefer to catch up here? Read the weekly briefing.

RSS feed